PRELUDE THERAPEUTICS INC Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
PRELUDE THERAPEUTICS INC (PRLD) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 18.62 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-11
- PRELUDE THERAPEUTICS INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 18.16M shares, a 5.14% increase year-over-year.
- PRELUDE THERAPEUTICS INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 17.27M shares, a 16.07% increase year-over-year.
- PRELUDE THERAPEUTICS INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 14.88M shares, a 21.83% increase year-over-year.
- PRELUDE THERAPEUTICS INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 12.22M shares, a 34.00% increase year-over-year.
- PRELUDE THERAPEUTICS INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 14.95M shares, a 4.76% increase from fiscal 2024.
- PRELUDE THERAPEUTICS INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 14.27M shares, a 18.62% increase from fiscal 2023.
- PRELUDE THERAPEUTICS INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 12.03M shares, a 23.28% increase from fiscal 2022.
- PRELUDE THERAPEUTICS INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 9.76M shares, a 24.92% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 18.62M shares 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | 18.16M shares 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | 14.95M shares 10-K · filed 2026-03-10 | |||
| 2025-09-30 | 15.92M shares 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | 16.82M shares 10-Q · filed 2026-08-11 | |||
| 2025-03-31 | 17.27M shares 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | 14.27M shares 10-K · filed 2026-03-10 | |||
| 2024-09-30 | 15.21M shares 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | 15.26M shares 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | 14.88M shares 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | 12.03M shares 10-K · filed 2025-03-10 | |||
| 2023-09-30 | 12.38M shares 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | 12.29M shares 10-Q · filed 2024-08-12 | |||
| 2023-03-31 | 12.22M shares 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | 9.76M shares 10-K · filed 2024-02-15 | |||
| 2022-09-30 | 9.69M shares 10-Q · filed 2023-11-01 | |||
| 2022-06-30 | 9.44M shares 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | 9.12M shares 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | 7.81M shares 10-K · filed 2023-03-15 | |||
| 2021-09-30 | 8.84M shares 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | 7.64M shares 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | 7.74M shares 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | 8.05M shares 10-K · filed 2022-03-17 | |||
| 2020-09-30 | 7.96M shares 10-Q · filed 2021-11-12 | |||
| 2020-06-30 | 31.98M shares 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | 32.17M shares 10-Q · filed 2021-05-11 | |||
| 2019-12-31 | 22.97M shares 10-K · filed 2021-03-16 | |||
| 2019-09-30 | 22.95M shares 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |